Crinetics Pharmaceuticals Inc (CRNX) expanding its growth trajectory ahead

With 1.86 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.78 million shares. The 52-week range on CRNX shows that it touched its highest point at $40.79 and its lowest point at $15.23 during that stretch. It currently has a 1-year price target of $49.33. Beta for the stock currently stands at 0.62.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRNX was up-trending over the past week, with a rise of 17.47%, but this was up by 13.42% over a month. Three-month performance surged to 34.42% while six-month performance rose 151.09%. The stock gained 122.48% in the past year, while it has gained 20.18% so far this year. A look at the trailing 12-month EPS for CRNX yields -3.64 with Next year EPS estimates of -3.62. For the next quarter, that number is -0.87. This implies an EPS growth rate of 9.39% for this year and -8.35% for next year.

Float and Shares Shorts:

At present, 66.80 million CRNX shares are outstanding with a float of 61.15 million shares on hand for trading. On Feb 15, 2024, short shares totaled 4.51 million, which was 6.76% higher than short shares on Jan 12, 2024. In addition to CROX as the firm’s Crocs, Inc., CRNT serves as its Ceragon Networks Ltd.

Institutional Ownership:

Through their ownership of 110.80% of CRNX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRNX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRNX analysts setting a high price target of $62.00 and a low target of $35.00, the average target price over the next 12 months is $48.23. Based on these targets, CRNX could surge 45.0% to reach the target high and fall by -18.15% to reach the target low. Reaching the average price target will result in a growth of 12.79% from current levels.

Dividends & Yield:

In terms of dividends, CRNX has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and CRNX currently yields $0.00. In the past year, CRNX’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, CRNX has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.

Summary of Insider Activity:

Insiders traded CRNX stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 3,000 shares were sold. The number of buy transactions has increased to 22 while that of sell transactions has risen to 18 over the past year. The total number of shares bought during that period was 520,950 while 373,400 shares were sold.